Fluphenazine Hcl
Brand names: Fluphenazine Hcl
At a glance
- Medicare prescriptions, 2024
- 163,664
- Medicare drug cost
- $20.4M
- Average cost per prescription
- $124
- Clinicians who prescribed it
- 6,221
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Fluphenazine hydrochloride tablets are indicated in the management of manifestations of psychotic disorders. Fluphenazine hydrochloride has not been shown effective in the management of behavioral complications in patients with mental retardation.
From the FDA-approved prescribing information (label dated April 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatry 42.5%
- Psychiatric Nurse Practitioners 27.8%
- Nurse Practitioners 8.5%
- Internal Medicine 7.6%
- Family Medicine 4.9%
- Physician Assistants 3.3%
- Child & Adolescent Psychiatry 1.5%
- Geriatric Medicine 1.3%
- General Practice 0.6%
- Neurology 0.5%
- Hospitalist 0.4%
- Emergency Medicine 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 13% from 2019 to 2024.
Biggest change by state since 2019
- Illinois +26%
- Michigan +3%
- Wisconsin −0%
- New Jersey −7%
- Alabama −9%
- California (smallest change) −25%
- Florida (smallest change) −22%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Amneal Pharmaceuticals Ny LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 1 mg | white round tablet, 6 mm | D5 |
| 2.5 mg | yellow round tablet, 6 mm | E4 |
| 5 mg | green round tablet, 6 mm | E1 |
| 10 mg | orange round tablet, 6 mm | E2 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Aug 2026 · Ajanta Pharma USA Inc · Class III
Failed impurities/degradation specifications: (OOS) for Organic Impurities by HPLC (Impurity-A) during testing at the 18 months long term stability. Result: 1.1 percent. Spec: 1.0 percent. - Mar 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.